{"id":"NCT03087773","sponsor":"Medical University of Graz","briefTitle":"Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction","officialTitle":"Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-11","primaryCompletion":"2022-05-03","completion":"2022-05-17","firstPosted":"2017-03-23","resultsPosted":"2024-08-22","lastUpdate":"2024-08-22"},"enrollment":476,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myocardial Infarction"],"interventions":[{"type":"DRUG","name":"Empagliflozin 10 mg","otherNames":["Jardiance"]},{"type":"DRUG","name":"Placebo Oral Tablet","otherNames":["Sugar pill"]}],"arms":[{"label":"Empagliflozin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo Oral Tablet","type":"PLACEBO_COMPARATOR"}],"summary":"This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.","primaryOutcome":{"measure":"Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels","timeFrame":"26 weeks","effectByArm":[{"arm":"Empagliflozin","deltaMin":-84.9,"sd":null},{"arm":"Placebo Oral Tablet","deltaMin":-82.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["Austria"]},"refs":{"pmids":["31901799","36036746","37407956","37475009","37777743","38287198","37236318","39297940","34693515"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":237},"commonTop":["Urinary tract infection","Genital fungal infection"]}}